Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Medical Director
Merck Sharp & Dohme LLC
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
234 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Chris Obrien Lifehouse ( Site 0300)
Camperdown, New South Wales, Australia
- Port Macquarie Base Hospital ( Site 0301)
Port Macquarie, New South Wales, Australia
- Riverina Cancer Care Center ( Site 0302)
Wagga Wagga, New South Wales, Australia
- Gallipoli Medical Research Ltd ( Site 0309)
Greenslopes, Queensland, Australia
- John Flynn Hospital & Medical Centre ( Site 0308)
Tugun, Queensland, Australia
- Box Hill Hospital ( Site 0304)
Box Hill, Victoria, Australia
- Monash Health ( Site 0305)
Clayton, Victoria, Australia
- Peter Maccallum Cancer Centre-Parkville Cancer Clinical Trials Unit (pcctu) ( Site 0306)
Melbourne, Victoria, Australia
- Fiona Stanley Hospital ( Site 0311)
Perth, Western Australia, Australia
- Ordensklinikum Linz Gmbh Elisabethinen ( Site 0901)
Linz, Upper Austria, Austria
- Landeskrankenhaus Salzburg - Universitatklinikum Der Pmu ( Site 0900)
Salzburg, Austria
- Krankenhaus Der Barmherzigen Brüder Wien ( Site 0904)
Vienna, Austria
- Medizinische Universität Wien ( Site 0903)
Vienna, Austria
- Oncocentro Ceara ( Site 2309)
Fortaleza, Ceará, Brazil
- Instituto de Cancer E Transplante de Curitiba Ictr ( Site 2306)
Curitiba, Paraná, Brazil
- Hospital Sao Vicente de Paulo ( Site 2303)
Passo Fundo, Rio Grande do Sul, Brazil
- Hospital de Clinicas de Porto Alegre ( Site 2304)
Porto Alegre, Rio Grande do Sul, Brazil
- Clinica de Oncologia Reichow ( Site 2308)
Blumenau, Santa Catarina, Brazil
- Fundacao Dr Amaral Carvalho ( Site 2302)
Jaú, São Paulo, Brazil
- Instituto Do Cancer Do Estado de Sao Paulo - Icesp ( Site 2305)
São Paulo, Brazil
- the Ottawa Hospital ( Site 0100)
Ottawa, Ontario, Canada
- Niagara Health System - St. Catharines ( Site 0107)
St. Catharines, Ontario, Canada
- Cisss de la Monteregie-Centre ( Site 0105)
Greenfield Park, Quebec, Canada
- Ciusss Ouest de L Ile - St-Mary S Hospital ( Site 0106)
Montreal, Quebec, Canada
- Centre Hospitalier de L Universite de Montreal - Chum ( Site 0109)
Montreal, Quebec, Canada
- Centre Intégré de Cancérologie Du Chu de Québec Université Laval, Hôpital de L'Enfant-Jésus ( Site 0101)
Québec, Quebec, Canada
- Centro Investigación del Cáncer James Lind ( Site 2401)
Temuco, Araucania, Chile
- Ic la Serena Research ( Site 2406)
La Serena, Coquimbo Region, Chile
- Clinica Universidad Catolica del Maule ( Site 2407)
Talca, Maule Region, Chile
- Bradfordhill ( Site 2403)
Santiago, Region M. de Santiago, Chile
- Clinica Alemana ( Site 2408)
Santiago, Region M. de Santiago, Chile
- Pontificia Universidad Catolica de Chile ( Site 2402)
Santiago, Region M. de Santiago, Chile
- Oncocentro ( Site 2400)
Viña del Mar, Valparaiso, Chile
- Beijing Cancer Hospital ( Site 0802)
Beijing, Beijing Municipality, China
- Peking University First Hospital ( Site 0800)
Beijing, Beijing Municipality, China
- Chongqing Cancer Hospital ( Site 0815)
Chongqing, Chongqing Municipality, China
- the First Affiliated Hospital of Xiamen University ( Site 0816)
Xiamen, Fujian, China
- the First Affiliated Hospital of Guangzhou Medical University-Urology ( Site 0837)
Guangdong, Guangdong, China
- Southern Medical University Nanfang Hospital ( Site 0838)
Guangzhou, Guangdong, China
- Sun Yat Sen Memorial Hospital ( Site 0819)
Guangzhou, Guangdong, China
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 12 Feb 2020
- Primary completion
- 31 Oct 2022
- Completion
- 8 Apr 2026
- Last update posted
- 29 Apr 2026
- Registered enrollment
- 1,251
- Registry id
- NCT04191096
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.